Dr. Shaji Kumar on MRD in Multiple Myeloma

Shaji Kumar, MD
Published: Monday, Oct 10, 2016


Shaji Kumar, MD, professor of Medicine at Mayo Clinic, discusses how minimal residual disease (MRD) testing has evolved in multiple myeloma.
 
The concept of MRD testing has been around for a long time in hematological malignancies, mainly in chronic myeloid leukemia (CLL), which has a very defined disease-related genetic change, says Kumar. However, it has been different in other diseases that are more heterogeneous, he says.
 
Now more effective treatment combinations are available that can produce very high response rates in multiple myeloma. The current response criteria do not adequately provide the ability to understand and measure those deep responses and compare them between trials, says Kumar.
 
To clarify best practices, the International Myeloma Working Group recently released updated consensus criteria for response and MRD assessment in multiple myeloma.

Shaji Kumar, MD, professor of Medicine at Mayo Clinic, discusses how minimal residual disease (MRD) testing has evolved in multiple myeloma.
 
The concept of MRD testing has been around for a long time in hematological malignancies, mainly in chronic myeloid leukemia (CLL), which has a very defined disease-related genetic change, says Kumar. However, it has been different in other diseases that are more heterogeneous, he says.
 
Now more effective treatment combinations are available that can produce very high response rates in multiple myeloma. The current response criteria do not adequately provide the ability to understand and measure those deep responses and compare them between trials, says Kumar.
 
To clarify best practices, the International Myeloma Working Group recently released updated consensus criteria for response and MRD assessment in multiple myeloma.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x